Compare Bristol-Myers Squibb Co (BMY) vs Nvidia Corp (NVDA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Nvidia Corp — how do they compare? Bristol-Myers Squibb Co trades at $63.53 (market cap $132.45B), while Nvidia Corp trades at $219.53 (market cap $5.27T). The key difference: Nvidia Corp is far larger — about 39.8× Bristol-Myers Squibb Co's market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.89%). Which is the better fit depends on your goals.
| BMY | NVDA | |
|---|---|---|
Market Cap | $132.45B | $5.27T |
Sector | Health | Technology |
52-Week High | $65.89 | $235.75 |
52-Week Low | $42.60 | $165.17 |
Enterprise Value | $166.44B | $5.20T |
Dividend Yield | 3.89% | 0.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
NVIDIA (NVDA) trades at $217.56, down 2.86% on the day, amid a broader tech sell-off. The stock maintains a bullish technical outlook with strong moving averages, though the 6-day RSI suggests overbought conditions near-term. Fundamentally, the company reported record revenue of $130.5B in 2025 with a net income margin of 62.97%, driven by AI chip demand. Recent earnings have consistently beaten estimates, and the company announced a $0.25 dividend payable in June 2026.
Outlook remains positive given NVIDIA's dominance in AI infrastructure, with a consensus price target of $325.86 implying significant upside. Risks include heightened valuations, competitive pressures, and macroeconomic sensitivity. Investor sentiment is buoyed by analyst optimism, with 75% recommending Buy, but news highlights concerns over growth sustainability as the company scales.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Nvidia Corp
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →
